Abstract:Background and Aim. Sphingosine kinase 1 (SPHK1) is a key enzyme of sphingolipid metabolism which is involved in the pathogenesis and progression of human cancer. It has been demonstrated to be upregulated in various types of human malignancies. However, the prognostic value of SPHK1 remains unclear. Therefore, we performed this meta-analysis to assess its predictive value in the prognosis of cancer patients. Methods. PubMed, Web of Science, Embase, CNKI, and Wanfang databases were thoroughly searched for eligible studies, in which the relationship between SPHK1 expression and cancer prognosis was evaluated. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to estimate the impact of SPHK1 expression on cancer patients’ survival. Odds ratios (ORs) and 95% CIs were combined to assess the association between SPHK1 expression and clinicopathological characteristics of cancer patients. The certainty of evidence was evaluated by Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria. Results. Thirty studies comprising 32 cohorts with 5965 patients were included in this meta-analysis. The outcomes indicated that elevated SPHK1 expression was associated with worse overall survival (OS) ( HR = 1.71 , 95% CI: 1.45-2.01, P < 0.001 ) and disease-free survival (DFS) ( HR = 1.34 , 95% CI: 1.13-1.59, P = 0.001 ). What is more, SPHK1 overexpression was significantly correlated with certain phenotypes of tumor aggressiveness, such as clinical stage ( OR = 2.07 , 95% CI: 1.39-3.09, P < 0.001 ), tumor invasion ( OR = 2.16 , 95% CI: 1.47-3.18, P < 0.001 ), lymph node metastasis ( OR = 2.04 , 95% CI: 1.71-2.44, P < 0.001 ), and distant metastasis ( OR = 3.16 , 95% CI: 2.44-4.09, P < 0.001 ). The quality of the evidence for both OS and DFS was low. Conclusions. Increased SPHK1 expression is related to poor prognosis in human cancers and may serve as a promising prognostic marker and therapeutic target for malignant patients. However, conclusions need to be treated with caution because of lack of high quality of evidence.

The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer.

The Clinicopathological and Prognostic Implications of Tyrosine Phosphatase SHP2 and Ankyrin Hook1 Gene Expression in Non- Small Cell Lung Cancer Patients Treated with Gemcitabine Plus Platinum As First-Line Chemotherapy

SHP2 Positively Regulates TGFβ1-induced Epithelial-Mesenchymal Transition Modulated by Its Novel Interacting Protein Hook1

Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer.

Prognostic Significance of SHP2 (PTPN11) Expression in Solid Tumors: A Meta-Analysis.

Roles of protein tyrosine phosphatase SHP2 in lung cancer

Role of SHP2/PTPN11 in the occurrence and prognosis of cancer: A systematic review and meta-analysis

High expression of SHP2 predicts a promising prognosis in colorectal cancer

High SHP2 expression determines the efficacy of PD ‐1/ PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

Increased Sphingosine Kinase 1 Expression is Associated with Poor Prognosis in Human Solid Tumors: A Meta-Analysis

PTPN11/Shp2 Overexpression Enhances Liver Cancer Progression and Predicts Poor Prognosis of Patients.

Shp2 Promotes Laryngeal Cancer Growth Through The Ras/Raf/Mek/Erk Pathway And Serves As A Prognostic Indicator For Laryngeal Cancer

Co-expression of PD-L1 and HIF-1α Predicts Poor Prognosis in Patients with Non-small Cell Lung Cancer after Surgery.

Prognostic Value of Elevated SHIP2 Expression in Laryngeal Squamous Cell Carcinoma

Elevated of HSP90 associates with expression of EGFR levels and predicts poor prognosis in non-small cell lung cancer patients

Prognostic significance of sphingosine kinase 2 expression in non-small cell lung cancer

Prognostic value of SH3PXD2B (Tks4) in human hepatocellular carcinoma: a combined multi-omics and experimental study

SHP2 Associates with Nuclear Localization of STAT3: Significance in Progression and Prognosis of Colorectal Cancer

Involvement of CHP2 in the Development of Non-Small Cell Lung Cancer and Patients' Poor Prognosis

SH2B1 Promotes NSCLC Cell Proliferation Through PI3K/Akt/mTOR Signaling Cascade